Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?

Executive Summary

Perrigo previously saw value in keeping its prescription pharmaceuticals in-house, but now says it will sell off or spin out the topical generics to focus on its over-the-counter brands. Questions remain about whether the company's generics portfolio is valuable enough to stand alone or attract a buyer.


Related Content

Perrigo Expanding Consumer Portfolio After Finding Problems Slowing Growth
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value
Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone
Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division
Perrigo Taps CEO With Global Operations Expertise At Pharma Packaging Firm
Generic Manufacturers Try To Up Their Game As US Pressure Persists
Starboard-Driven Perrigo Sees CEO Depart After CFO
Starboard Agreement Tilts Perrigo Toward Rx Generics Sale
Perrigo Puts Tysabri On Block, Generic Topicals Under Microscope
Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts